CVRx reports Q1 EPS (53c), consensus (57c)

Reports Q1 revenue $12.35M, consensus $12.3M. “We’re encouraged about the momentum building in our business as we move into the second quarter,” said Kevin Hykes, President and Chief Executive Officer of CVRx (CVRX). “While revenue growth in the first quarter didn’t meet our expectations, we added a significant number of new sales representatives, and are very pleased with the talent we have attracted to the organization. As these reps are still in the early stages of building their territories, we expect their contributions to grow as the year progresses. We continue to support these commercial initiatives by advancing our growing body of clinical evidence, highlighted by our recently published hospitalization data from the Premier Healthcare Database, which further reinforced Barostim’s value proposition in the treatment of heart failure patients.”